Healthgen recombinant human serum albumin (rHSA) has excellent
batch consistency. Using self-pollination rice as the bioreactor to
express the rHSA, with the world's advanced facility and top
production proceeding to extract and purify the rHSA, Healthgen can
ensure the excellent consistency of rHSA from different batches.
Compared with the plasma HSA, rHSA has the same amino acids
sequence, molecular weight, N- and C terminus, PI and crystal
structure as plasma HSA.
|Amino Acids Sequence||Same||Same|
|Thermal Stability||M/P 65℃||M/P 65℃|
Peptide mapping of rHSA and pHSA. Peptide sequences highlighted in
bold indicate peptide sequences of HSA sequence in a database. Blue
and red letters show the amino acids in rHSA and pHSA matched with
database sequence, respectively.
Healthgen Biotechnology Corp. has been committed in research of
protein purification, meanwhile our technology has been patented by
the US Patent and Trademark Office on May 15th 2015 and been
granted the patent of "A method for isolating and purifying
recombinant human serum albumin from transgenic rice grain", which
patent number is US9, 023,990. Now, our rHSA purity can be as high
as 99%. rHSA, manufactured in a GMP compliance facility with
rigorous quality control procedures, performs superior
Compared with the commercial rHSA, Healthgen rHSA has no
degradation fragment and fewer polymers.
Human serum albumin has been widely used as plasma expansion
reagent. Because of its non-enzymatic activity and no
immunogenicity, etc. HSA can also be used as excipient and
stabilizer in a variety of pharmaceutical preparations and
serum-free cell culture medium component. In addition, HSA is also
used as a drug carrier due to its antioxidant properties, thereby
conferring drugs better physicochemical properties. At present,
most HSA products in the market are directly derived from human
On the one hand, due to the potential existence of various
infectious disease pathogens in the human blood, especially AIDS,
hepatitis B and other viruses. Thereby, these virus from human
plasma will be brought with HSA to the final products. rHSA
produced by plant derived recombinant proteins technology can
effectively avoid the risks of virus pollution and infection.
What’s more, the supply of human blood is limited. Therefore, it’s
very urgent to search blood substitutes. The establishment and
development of recombinant technology provide an important method
for the acquisition of biological materials. In recent years, many
researchers have been hotly committed to the recombinant human
serum albumin research.